ReviewJournal of controlled release : official journal of the Controlled Release Society2017
Glucose-responsive insulin release: Analysis of mechanisms, formulations, and evaluation criteria.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Design strategies for chemical-stimuli-responsive programmable nanotherapeutics.Drug discovery today · 2019Pooled it
- Biocompatible Nanogels Synthesized via RAFT Polymerization for Long-Acting Onset-Controllable Glucose-Responsive Insulin Delivery in Diabetic Mice.Advanced functional materials · 2026Article
- PVA Nanofibers by Solution Blow Spinning: Processing Principles, Challenges, and Biomedical Applications.Polymers · 2026Review
- Engineering core-shell polymer microgels to control the onset of glucose-regulated insulin release.Journal of biomaterials science. Polymer edition · 2026Article
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.Biomedical microdevices · 2026Article
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.AAPS PharmSciTech · 2025Review
- Multifunctional Biomedical Devices with Closed-Loop Systems for Precision Therapy.Advanced healthcare materials · 2025Review
- Integrated individually addressable microneedle arrays for robust glucose monitoring and on-demand insulin releasing.Microsystems & nanoengineering · 2025Article
- Review
- Recent Insights into Glucose-Responsive Concanavalin A-Based Smart Hydrogels for Controlled Insulin Delivery.Gels (Basel, Switzerland) · 2024Review
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- "Smart" Matrix Microneedle Patch Made of Self-Crosslinkable and Multifunctional Polymers for Delivering Insulin On-Demand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- pH-Responsive Hexa-Histidine Metal Assembly (HmA) with Enhanced Biocatalytic Cascades as the Vehicle for Glucose-Mediated Long-Acting Insulin Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Microneedle-based insulin transdermal delivery system: current status and translation challenges.Drug delivery and translational research · 2022Review
- Emerging Theranostic Nanomaterials in Diabetes and Its Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- A Zwitterionic Polyurethane Nanoporous Device with Low Foreign-Body Response for Islet Encapsulation.Advanced materials (Deerfield Beach, Fla.) · 2021Article
- Developing Insulin Delivery Devices with Glucose Responsiveness.Trends in pharmacological sciences · 2021Review
- Microenvironment Activatable Nanoprodrug Based on Gripper-like Cyclic Phenylboronic Acid to Precisely and Effectively Alleviate Drug-induced Hepatitis.Theranostics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Diabetes mellitus has become one of the biggest medical challenges affecting millions of people globally. Alternative treatments for diabetes are currently being intensively investigated to improve the treatment efficacy and life qualities for diabetic patients. Glucose-responsive insulin release (GRIR) systems have exhibited tremendous potential to improve the normal glycemic control and to reduce the incidence of hyperglycemia and hypoglycemia, which further reduces potential complications in diabetic patients. In a given GRIR drug formulation, accuracy, response time, and reversibility of the GRIR functions are three key features enabling potential seamless control of blood glucose level. Nevertheless, there is significant challenge preventing current GRIR formulations from achieving them. This review article analyzes the most updated literature and provides insights on the impact of GRIR mechanisms, and formulations on these key features, and the relevant in vitro and in vivo evaluation methods to test these functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.